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Cyclosporine exacerbates ketamine toxicity in
zebrafish: Mechanistic studies on drug–drug
interaction
Bonnie L. Robinson, Melanie Dumas, Syed F. Ali, Merle G. Paule, Qiang Gu
and Jyotshna Kanungo*
ABSTRACT: Cyclosporine A (CsA) is an immunosuppressive drug commonly used in organ transplant patients to prevent allograft
rejections. Ketamine is a pediatric anesthetic that noncompetitively inhibits the calcium-permeable N-methyl-D-aspartic acid
receptors. Adverse drug–drug interaction effects between ketamine and CsA have been reported in mammals and humans.
However, the mechanism of such drug–drug interaction is unclear. We have previously reported adverse effects of combination
drugs, such as verapamil/ketamine and shown the mechanism through intervention by other drugs in zebrafish embryos. Here,
we show that ketamine and CsA in combination produce developmental toxicity even leading to lethality in zebrafish larvae
when exposure began at 24 h post-fertilization (hpf ), whereas CsA did not cause any toxicity on its own. We also demonstrate
that acetyl L-carnitine (ALCAR) completely reversed the adverse effects. Both ketamine and CsA are CYP3A4 substrates. Although
ketamine and CsA independently altered the expression of the hepatic marker CYP3A65, a zebrafish ortholog of human CYP3A4,
both drugs together induced further increase in CYP3A65 expression. In the presence of ALCAR, however, CYP3A65 expression
was normalized. ALCAR has been shown to prevent ketamine toxicity in mammal and zebrafish. In conclusion, CsA exacerbated
ketamine toxicity and ALCAR reversed the effects. These results, providing evidence for the first time on the reversal of the
adverse effects of CsA/ketamine interaction by ALCAR, would prove useful in addressing potential occurrences of such toxicities
in humans. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
Keywords: ketamine; zebrafish; acetyl l-carnitine; cyclosporine; CYP3A65

Introduction
Cyclosporine A (CsA), a neutral hydrophobic cyclic peptide of 11
amino acids, is a potent immunosuppressant used in organ
transplantation patients and for treating various autoimmune
diseases (Conde et al., 2008). The use of CsA, however, has been
associated with a number of side effects that include neurotoxicity
(Chang et al., 2001), hepatotoxicity (Galan et al., 1995),
nephrotoxicity (Woolfson and Neild, 1997) and hypertension
(Textor et al., 1994). Interaction of CsA with other drugs has been
shown to cause altered blood levels of the drugs, a decrease or
increase in effectiveness and side effects of both CsA and the
co-administrated drugs (Backman et al., 2006; Neuvonen et al.,
2006). Ketamine, a pediatric anesthetic, is an antagonist of
N-methyl-D-aspartate (NMDA)-type glutamate receptors (Kohrs
and Durieux, 1998). Ketamine is listed as a schedule III controlled
substance in the USA, due to its potential for abuse (Morgan
et al., 2010; Rowland, 2005). It is also widely used in veterinary
medicine to induce anesthesia and relieve postoperative pain
(Wright, 1982). In many animal species including horses, ketamine
is administered in combination with xylazine, diazepam and other
compounds to avoid adverse effects associated with ketamine
(Hazra et al., 2008; Sinclair and Valverde, 2009). Although,
xylazine/ketamine administration is considered safe for anesthesia
in rats (Saranteas et al., 2005), high mortality in CsA-treated rats
when anesthetized with a common intraperitoneal dose of
xylazine (10 mg kg1 body weight) and ketamine (100 mg kg1
body weight) has been reported (Loeffelbein et al., 2010).
Furthermore, in rats, a reduced ketamine dose, but not the xylazine
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dose resulted in a significant increase in survival rate indicating
that CsA and ketamine interaction are likely to occur (Loeffelbein
et al., 2010). Therefore, the need to reduce the anesthetic dose
of ketamine in CsA-treated rats by about 40% has been
recommended (Loeffelbein et al., 2010).
Intraperitoneal application of xylazine/ketamine for anesthesia
in rats co-administered with CsA caused high mortality possibly
due to respiratory arrest brought upon by a relative overdose
potentially resulting from altered cytochrome P (CYP)450 enzyme
expression by CsA (Sato et al., 2007). Ketamine is a substrate of
CYP3A4 in rats (Meneguz et al., 1999). It was therefore assumed
that the dose reduction for ketamine in CsA-pretreated rats might
be related to slower drug metabolism (Loeffelbein et al., 2010).
Marked variation in response to drugs among individuals is
suggested to be associated with differences in CYP3A expression
(Dresser et al., 2000). When pre-treated with other drugs such as
chloramphenicol, cimetidine, ketoconazole or SKF 525-A
(substrates of CYP3A), prolonged anesthesia and increased
mortality after xylazine/ketamine administration in rats were
reported (Amouzadeh et al., 1989). The interaction of CsA with
barbiturates (anesthetic drugs) in mice also induced prolonged
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sleeping time (Sato et al., 2007). Furthermore, ketamine in a patient
immunosuppressed with CsA has been shown to be unsafe as
both the drugs with possible proconvulsant properties induced
generalized tonic clonic seizures (Agarwal et al., 2005).
The immunosuppressant property of CsA is based on its ability
to inhibit calcineurin signaling (Yu et al., 2013). Although CsA is
the first choice of drug during organ transplantation, it has
been shown to cause serious nephrotoxicity, hepatotoxicity,
neurotoxicity and cardiotoxicity (Rezzani, 2004). Drug–drug
interactions pose serious issues for human health. Many drug–
drug interactions can result due to alterations in their metabolic
enzymes (e.g., CYPs), which are mostly expressed in the liver and
gut. During co-administration, while some drugs act as inducers
of the enzyme(s), others act as inhibitors. Zebrafish embryos and
larvae in recent years have been used as alternative in vivo toxicity
screening models for teratogenesis as well as organ-specific
toxicities in the early drug discovery process (Eimon and
Rubinstein, 2009; Kanungo et al., 2014; McGrath and Li, 2008).
Zebrafish larvae have a fully functional liver at 72 hpf and they
express 94 CYP enzymes, most being human orthologs (Goldstone
et al., 2010). As in humans, zebrafish CYP1–4 enzymes metabolize
xenobiotics, while the zebrafish CYP3A65 has been identified as
the ortholog of the human CYP3A4 (Goldstone et al., 2010; Hill
et al., 2012; McGrath and Li, 2008). Similar to human CYP3A,
enhanced CYP3A65 transcription in the foregut of the zebrafish
larvae in response to dexamethasone and the antibiotic rifampicin
confirmed that zebrafish CYP3A65 is an ortholog of the human
CYP3A gene (Chang et al., 2013; Tseng et al., 2005). CYP3A65
expression in zebrafish has been used as a hepatic biomarker
(Al-Habsi et al., 2016; Cunha et al., 2016; Verstraelen et al., 2016;
Xia et al., 2016) and the zebrafish embryo model was shown to
detect hepatotoxicants with higher specificity than the HepG2
cells ( Jones et al., 2009).
The objective of the present study was to assess CsA/ketamine
drug–drug interaction effects on the zebrafish larvae and to
elucidate potential mechanisms by reversing the adverse effects
with a third drug. Additionally, evaluation of the CYP3A65
(zebrafish ortholog of the human CYP3A4) expression was
undertaken to determine possible link to the drug interaction
effects.

Materials and methods
Animals
Adult wild-type zebrafish (Danio rerio, AB strain) were obtained
from the Zebrafish International Resource Center (www.zirc.org)
(Eugene, OR, USA). The fish were kept in fish tanks (Aquatic
Habitats, FL, USA) at the NCTR/FDA zebrafish facility containing
buffered water (pH 7.5) at 28°C, and were fed daily live brine
shrimp and Zeigler dried flake food (Zeiglers, Gardeners, PA,
USA). Each 3 liter tank housed eight adult males or females.
Handling and maintenance of zebrafish complied with the NIH
Guide for the Care and Use of Laboratory Animals and were
approved by the NCTR/FDA IACUC. The day/night cycle was
maintained at 14/10 h. For in-system breeding, crosses of males
and females were set up the previous day with partitions that were
taken off the following morning at the time of light onset at
07.30 h to stimulate spawning and fertilization. Fertilized eggs
were collected from the bottom of the tank as soon as they were
laid. The eggs were placed in Petri dishes and washed thoroughly
with buffered egg water (reverse osmosis water containing 60 mg
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sea salt [Crystal Sea®, Aquatic Eco-systems, Inc., Apopka, FL, USA]
per liter of water, pH 7.5]) and then allowed to develop in an
incubator at 28.5°C for later use.
Reagents
Ketamine hydrochloride was purchased from Vedco, Inc.
(St. Joseph, MO, USA). Acetyl L-carnitine (ALCAR) and CsA were
purchased from Sigma (St. Louis, MO, USA). ALCAR stock (1 M)
solutions were made fresh with buffered egg water. CsA stock
(10 mM) was prepared using dimethyl sulfoxide (DMSO) as the
solvent. All other reagents used in this study were purchased from
Sigma unless mentioned otherwise.
Treatment of zebrafish embryos with ketamine, cyclosporine a
and acetyl L-carnitine
As we previously reported, ALCAR at 0.5 mM did not have any
effect on the zebrafish embryo development when exposed for
20–24 h, and 0.1 mM ALCAR did not prevent ketamine-toxicity.
However, doses of 0.5 or 1.0 mM was effective in completely
inhibiting ketamine’s adverse effects (Cuevas et al., 2013; Guo
et al., 2017; Kanungo et al., 2012). Based on these data we chose
to use 1.0 mM ALCAR for all our experiments in the present study.
For ketamine dose, we have earlier determined that 2 mM
ketamine in water results in an internal exposure of the anesthetic
level of plasma concentrations in humans (Trickler et al., 2014). For
co-exposure to various drug combinations, the drugs were added
together at the same time. For the first experiment aimed at
elucidating ketamine and CsA interaction effects, treatment with
ketamine (2 mM), CsA (10 μM) and ALCAR (1.0 mM) was undertaken
using manually dechorionated 24 h postfertilization (hpf )
embryos. The specified doses of ketamine and ALCAR were used
based on our multiple earlier studies (Cuevas et al., 2013; Kanungo
et al., 2012, 2013; Lantz-McPeak et al., 2015; Trickler et al., 2014). We
used 10 μM CsA to elicit maximal effect of ketamine and CsA
combination effects so as to determine whether ALCAR was
effective against the drastic adverse effects. For each treatment
10 embryos were placed in each well of the six-well plates
containing 5 ml buffered egg water (reverse osmosis water
containing 60 mg sea salt [Crystal Sea®; Aquatic Eco-systems, Inc.,
Apopka, FL, USA] per liter of water, pH 7.5). Five replicates for each
group were set up with a total of 50 embryos for each treatment
group. The control group received 5 μl of DMSO (vehicle) with a
final concentration of (0.1%). The experiment was repeated three
times. Static exposure continued for 72 h. Beginning 72 hpf,
zebrafish embryos are called larvae instead of embryos. The effects
of the drugs were assessed in the larvae at 96 hpf. Survival of the
larvae was scored using all five replicates (n = 50). Body length
was measured for all surviving larvae in the 2 mM ketamine +10
μM CsA group (of 50). For other groups, body length was measured
for two larvae from each well (n = 10). Images of the embryos and
larvae were acquired using a DP2 BSW microscope (Olympus,
Tokyo, Japan). Body length was quantitated using a DP2 BSW
microscope digital camera software (Olympus).
In the second set of experiments, 6 hpf embryos (with chorions
intact) were used. The embryos (n = 10 per well of a six-well plate
in 5 ml buffered egg water) were exposed for 24 h (actual age of
endpoint assessment is 30 hpf ), 48 h (actual age of endpoint
assessment is 54 hpf ) and 72 h (actual age of endpoint
assessments is 78 hpf ) with 5 μl DMSO, 2 mM ketamine, 10 mM
CsA, 2 mM ketamine +10 μM CsA, 2 mM ketamine + 1.0 mM ALCAR,
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2 mM ketamine +10 μM CsA + 1.0 mM ALCAR. The experiment was
repeated three times. Images of the embryos and larvae were
acquired using a DP2 BSW microscope. Body length was
quantitated (n = 10) using a DP2 BSW microscope digital camera
software.
For the third set of experiments aimed at mechanistic studies, a
shorter exposure (24 h) of 72 hpf larvae was designed to avoid
deformity and mortality. The 72 hpf larvae have guts and livers
(Wilkins and Pack, 2013) that express drug-metabolizing CYP
enzymes (Chang et al., 2013). In a six-well plate, each well
containing 10 larvae (72 hpf ), exposure to 2 mM ketamine in the
presence or absence of various sublethal doses of CsA (0.5, 1.0,
2.0 and 5.0 μM) was performed. Another group received ALCAR
(1.0 mM) in addition to 2 mM ketamine and 5.0 μM CsA. Untreated
control groups (exposed to equivalent amount of the vehicle,
DMSO) were examined in parallel. Images of the embryos and
larvae were acquired using a DP2 BSW microscope. Body length
was quantitated (n = 10) using a DP2 BSW microscope digital
camera software.
The statistical significance of the effects of the various
treatments on survival and body length was determined by oneway ANOVA (Sigma Stat) using Holm–Sidak pairwise multiple
comparison post-hoc analysis. Statistical significance was based
on P < 0.05.
RNA extraction and cDNA synthesis
Total RNA (from 50 pooled larvae per treatment group) was
extracted from whole larvae using the Trizol reagent (Invitrogen,
Carlsbad, CA, USA). An aliquot of each RNA sample was used to
determine spectrophotometrically (using a NanoDrop ND-1000;
NanoDrop Technology, Wilmington, DE, USA) the RNA quality
(A260/A280 > 2.0) and concentration. First-strand cDNA was
synthesized from total RNA (2 μg; 20 ml final reaction volume) with
oligo(dT) priming using SuperScript II reverse transcriptase
(Invitrogen) according to the manufacturer’s instructions.
Primers
Zebrafish gene-specific primers (Table 1) were used for the realtime quantitative reverse transcription polymerase chain reaction
(RT-qPCR) assays to quantify GAPDH and CYP3A65 (GenBank entry
no. NM_001037438.1).
Real-time quantitative reverse transcription polymerase chain
reaction assay for gene expression analysis
Real-time qPCR was performed using a CFX96 C1000 (Bio-Rad,
Hercules, CA, USA) detection system with SYBR green fluorescent
label (Bio-Rad). Samples (25 μl final volume) contained the
following: 1× SYBR green master mix (Bio-Rad), 5 pmol of each
primer and 0.25 μl of the reverse transcription reaction mixture.
Samples were run in triplicate in optically clear 96-well plates.
Cycling parameters were as follows: 50°C 2 min, 95°C 10 min,

then 40 cycles of 95°C 15 s, 60°C 1 min. A melting temperaturedetermining dissociation step was performed at 95°C 15 s,
60°C 15 s and 95°C 15 s at the end of the amplification phase.
The 2ΔΔCt method was used to determine the relative gene
expression (Livak & Schmittgen, 2001). The GAPDH gene was
the internal control for all qPCR experiments. Data from each
group (n = 3) were averaged and shown as normalized gene
expression with SD. One-way ANOVA (Sigma-Stat) and Holm–
Sidak pairwise multiple comparison post-hoc analyses were
used to determine statistical significance. Statistical significance
was based on P < 0.05.

Results
Acetyl L-carnitine protects zebrafish embryos/larvae from
toxicities induced by ketamine and cyclosporine a
Manually dechorionated 24 hpf zebrafish embryos were treated
with either 2 mM ketamine or 10 μM CsA for 72 h. Compared to
control, at 96 hpf, 2 mM ketamine induced developmental toxicity
(Fig. 1A) with no mortality (Fig. 1B). The observed developmental
toxicity included an edematous pericardium and significantly
reduced linear body length (Fig. 1A,C). CsA on the other hand
did not have any effects on either the pericardium (Fig. 1A) or body
length (Fig. 1C). However, 2 mM ketamine in the presence of 10 μM
CsA induced severe deformity in the larvae (Fig. 1A) and 80%
mortality (Fig. 1B). The moderate toxicity induced by ketamine
and severe toxicity on the overall development and survival
induced by ketamine and CsA together were prevented with
1.0 mM ALCAR (Fig. 1A–C).
When treatment started at 6 hpf, developmental trends were
similar to what occurred when 24 hpf embryos were treated. When
compared to control and ALCAR co-treated embryos, embryos
with 24 h of exposure (actual age 30 hpf ) to ketamine and
ketamine/CsA showed retarded overall development with less
pigmentation and smaller eyes being the most obvious indicators
(Fig. 2, upper panel). Similar trends were also observed when
exposure continued up to 48 h (actual age of the embryos was
54 hpf ) (Fig. 2, lower panel). At 72 h of exposure, larvae (actual
age 78 hpf ) in the control and ALCAR co-treated groups were all
hatched and alive (Fig. 3A,C,E,F), although the ones exposed to
the drugs had significantly reduced body length (Fig. 3G). On the
other hand, larvae treated with ketamine or ketamine/CsA were
unhatched and severely malformed (Fig. 3B,D). Although ALCAR
prevented morphological deformity and mortality of the larvae
treated with ketamine and ketamine/CsA, compared to control
(Fig. 3A), these larvae had significantly reduced body length (Fig. 3E,F). Even larvae treated with only CsA (10 μM) also exhibited
significantly shorter body length (Fig. 3C) than the control (Fig. 3A).
These results indicate that very early exposure (6 hpf gastrula stage
with intact chorions) results in incomplete reversal of ketamine
and CsA toxicity by ALCAR.
Based on these data, we chose to focus our study using 24 hpf
embryos or older for drug exposure as these embryos have all

Table 1. List of primers used in real-time quantitative polymerase chain reaction (RT-qPCR) assays
Gene
GAPDH
CYP3A65
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Forward primer

Reverse primer

50 -GATACACGGAGCACCAGGTT-30
50 -GAAACTGCAGGAGGAGATCG-30

50 -GCCATCAGGTCACATACACG-30
50 -CAAGTCTTTGGGGATGAGGA-30

Published 2017. This article is a U.S.
Government work and is in the public domain in the USA.

wileyonlinelibrary.com/journal/jat

B. L. Robinson et al.

Figure 1. ALCAR protects zebrafish embryos from toxicities induced by ketamine and CsA in combination. (A) Zebrafish embryos at 24 hpf (manually
dechorionated) were exposed (static exposure) for 72 h to: vehicle (dimethyl sulfoxide); 2 mM ketamine; 10 μ M CsA; 2 mM ketamine +10 μM CsA; 2 mM
ketamine +1.0 mM ALCAR; and 2 mM ketamine +10 μM CsA + 1.0 mM ALCAR. Images of 96 h larvae show severe pericardial edema (*). Ten embryos were
treated for each group in each experiment. Control groups were treated with 5 μl dimethyl sulfoxide (0.1%). The experiment was repeated five times. (B)
Survival percentage (n = 50) of the larvae (96 hpf ) as shown in (A). Data are presented as mean ± SD. Statistical significance (P < 0.05) is indicated (*). (C)
Linear body length (n = 10) was measured using the DP2 BSW microscope digital camera software (Olympus). Data are presented as mean ± SD. Statistical
significance (P < 0.05) is indicated (*). ALCAR, acetyl L-carnitine; CsA, cyclosporine A.

Figure 2. ALCAR protects zebrafish embryos from toxicities resulting from early exposure of embryos to ketamine and ketamine/CsA. Zebrafish embryos at
6 hpf (with intact chorion) were exposed (static exposure) for 24 h (upper panel) and 48 h (lower panel) to: vehicle (dimethyl sulfoxide); 2 mM ketamine; 10 μM
CsA; 2 mM ketamine +10 μM CsA; 2 mM ketamine +1.0 mM ALCAR; and 2 mM ketamine +10 μM CsA + 1.0 mM ALCAR. Representative images of embryos (actual
age, 30 hpf [upper panel] and 54 hpf [lower panel], respectively) show morphological features that indicate differences in body pigmentation and eye size.
Ten embryos were treated for each group in each experiment. Control (vehicle) groups were treated with 5 μl dimethyl sulfoxide (0.1%). Experiment was
repeated three times. ALCAR, acetyl L-carnitine; CsA, cyclosporine A.

the organs or organ rudiments present and their response to the
drugs would be more comparable to whole organisms. The results
indicated that CsA exacerbated ketamine toxicity as CsA has no
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adverse effects on its own on the zebrafish larvae. ALCAR’s reversal
of the CsA and ketamine combination toxicity also confirmed
that it was ketamine toxicity that was intensified with CsA
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Figure 3. Early exposure of ketamine and ketamine/CsA in the absence of ALCAR causes extreme deformity in zebrafish embryos. Zebrafish embryos at 6
hpf (with intact chorion) were exposed (static exposure for 72 h) to: (A) vehicle (dimethyl sulfoxide); (B) 2 mM ketamine; (C) 10 μM CsA; (D) 2 mM ketamine +10
μM CsA; (E) 2 mM ketamine +1.0 mM ALCAR; and (F) 2 mM ketamine +10 μM CsA + 1.0 mM ALCAR. Representative images of embryos (actual age 78 hpf ) show
morphology. Ten embryos were treated for each group in each experiment. Control groups were treated with 5 μl dimethyl sulfoxide (0.1%). Experiment was
repeated three times. Linear body length (n = 10) was measured using the DP2 BSW microscope digital camera software (Olympus). Data are presented as
mean ± SD. Statistical significance (P < 0.05) is indicated (*). ALCAR, acetyl L-carnitine; CsA, cyclosporine A.

co-treatment, as our previous studies have established that ALCAR
prevents ketamine toxicity (Cuevas et al., 2013; Guo et al., 2017;
Kanungo et al., 2012).
Cyclosporine a dose-dependently exacerbates ketamine
toxicity
To determine whether CsA enhances ketamine toxicity in a dosedependent manner, we used 72 hpf zebrafish larvae. The goal
behind this experiment was to use larvae with livers and guts
(absent in 24 hpf embryos) that express drug-metabolizing
enzymes. We also used lower doses of CsA to avoid lethality and
to quantitate subtle endpoints of overall developmental changes.
The larvae were treated only for 24 h, once again ascertaining that
the effects would be milder and endpoints quantifiable. Postexposure, at 96 hpf, compared to control, 2 mM ketamine induced
pericardial edema in the larvae (Fig. 4A). Co-exposure to 2 mM
ketamine with increasing doses of CsA (0.5, 1.0, 2.0 and 5.0 μM)
produced significant reductions in body length (Fig. 4B) and all
the dose groups developed pericardial edema (Fig. 4A). ALCAR
(1.0 mM) co-treatment prevented these developmental defects
from occurring (Fig. 4A) and the body lengths of the larvae were
comparable to control (Fig. 4B). These results further confirmed
that CsA exacerbates ketamine toxicity dose-dependently and
ALCAR prevents it.
Ketamine and cyclosporine a induce CYP3A65 expression
CYP3A65 is the zebrafish ortholog of human CYP3A4. Ketamine and
CsA are substrates of the mammalian and human CYP3A4 enzyme.
We explored whether ketamine and CsA altered the expression of
CYP3A65 at the transcriptional level. Zebrafish larvae at 72 hpf were
exposed to various doses of ketamine or CsA for 24 h. Ketamine
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dose-dependently (0.5, 2.0 and 5.0 mM) induced CYP3A65
expression (Fig. 5A). CsA at various doses (0.5, 1.0, 2.0 and 5.0 μM)
also induced CYP3A65 expression (Fig. 5B). When 72 hpf larvae
were exposed for 24 h to 2 mM ketamine with increasing doses of
CsA (0.5, 1.0, 2.0 and 5.0 μM), the higher three doses (1.0, 2.0 and
5.0 μM) significantly upregulated CYP3A65 expression (Fig. 6A).
These results suggested that ketamine and CsA (1.0–5.0 μM)
together might alter their metabolism by modulating the
expression of CYP3A65.
Acetyl L-carnitine normalizes CYP3A65 expression induced by
ketamine and cyclosporine a
As ALCAR prevents ketamine toxicity as well as ketamine/CsA
combination toxicity, we explored whether it also differentially
affected CYP3A65 expression that is induced by both the drugs
alone or together. RT-qPCR analyses showed that ALCAR
normalized CYP3A65 expression in the presence of ketamine and
CsA (Fig. 6B). These results indicated that ALCAR has the ability
to prevent zebrafish larvae from potential hepatic dysfunction
induced by ketamine and CsA.

Discussion
CsA has been used as an immunosuppressant in organ
transplantation patients (Kahan, 1989) as well as for treating
immune diseases (Faulds et al., 1993) for more than three decades.
However, CsA’s efficacy is challenged by severe side effects, such
as nephrotoxicity, arterial hypertension and cancer progression
(Guada et al., 2016). High mortality occurred in CsA-treated rats
when anesthetized with ketamine (Loeffelbein et al., 2010). Hence,
a reduction in the anesthetic dose of ketamine in CsA-treated rats
by about 40% to avoid this adverse effect was recommended
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Figure 4. Dose-dependent effects of CsA on the zebrafish larvae in the presence of ketamine and ALCAR. (A) Zebrafish embryos at 72 hpf were exposed for
24 h to: 2 mM ketamine; 2 mM ketamine +0.5 μM CsA; 2 mM ketamine +1.0 μM CsA; 2 mM ketamine +2 μM CsA; 2 mM ketamine +5 μM CsA; and 2 mM ketamine
+5 μM CsA + 1.0 mM ALCAR. Ten embryos were treated for each group in each experiment. Control groups were treated with 2.5 μl dimethyl sulfoxide
(0.05%). Experiment was repeated three times. Images (lateral views) of the 96 hpf larvae are shown. Pericardial edema is marked with an asterisk. (B) Body
lengths of the larvae (n = 10) treated with ketamine, CsA and ALCAR as indicated above are presented as mean ± SD. Statistical significance (P < 0.05) is
indicated (*). ALCAR, acetyl L-carnitine; CsA, cyclosporine A.

(Loeffelbein et al., 2010). Ketamine in a patient immunosuppressed
with CsA has been shown to be unsafe as both the drugs induced
generalized tonic clonic seizures (Agarwal et al., 2005). Our results
with 24 hpf embryos co-treated with 10 μM CsA and 2 mM
ketamine for 72 h produced adverse effects with about 90%
mortality occurring in the 96 hpf larvae. The 10 μM (12 mg l1)
CsA concentration is higher than the 0.8–2 mg l1 in the serum
of patients who take CsA for immunosuppression (Keown, 2002);
although the internal CsA concentration in the zebrafish larvae
could presumably be much lower than 10 μM added to the water
as, in humans, bioabsorption of cyclosporine is significantly
decreased than the actual dose in humans (Drewe et al., 1992).
Additionally, in zebrafish embryos, other drugs, such as ketamine
and ethanol have been shown to have internal concentrations
of only about 0.4% and 0.86%, respectively (Ali et al., 2011;
Trickler et al., 2014). Ketamine and CsA co-treatment significantly
reduced body length in the surviving larvae compared to the
ketamine-treated larvae that showed no mortality despite being
significantly smaller than control.

wileyonlinelibrary.com/journal/jat

Mostly focusing on the overall development with a major
objective to reverse the adverse effects, we observed pericardial
edema in the larvae treated with ketamine alone. Surviving larvae
of the CsA/ketamine co-treatment group also showed pericardial
edema and a severely deformed body axis. As CsA-treated larvae
developed normally as control, it is plausible that CsA exacerbated
ketamine toxicity as reported in rats (Loeffelbein et al., 2010), mice
(Sato et al., 2007) and human (Agarwal et al., 2005). It is further
confirmed by the reversal of the adverse effects by ALCAR as
ALCAR has been shown to prevent ketamine toxicity in zebrafish
(Cuevas et al., 2013; Guo et al., 2017; Kanungo et al., 2012), rats
(Boctor and Ferguson, 2009) and cultured rat cortical neurons
in vitro (Zou et al., 2008). The results of ketamine/CsA toxicity
reversed by ALCAR may shed light on human conditions resulting
from CsA and ketamine interaction (http://www.ehealthme.com/
drug-interaction/ketamine%20hydrochloride/cyclosporine/).
In mammalian cells, ketamine induces a blockade of lipid
oxidation and a decrease in ATP content in rat heart, whereas
ALCAR facilitates fatty acid oxidation to support ATP production
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Figure 5. Ketamine and CsA alter the expression of CYP3A65 mRNA. (A)
Zebrafish larvae at 72 hpf were exposed for 24 h with 0.5, 2 and 5 mM
ketamine. Relative expression of CYP3A5 is presented (mean ± SD)
following qRT-PCR assessment of the cDNA synthesized from total RNA
isolated from these larvae. Statistical significance (P < 0.05) is indicated
(*). (B) Zebrafish larvae at 72 hpf were exposed for 24 h with 0.5, 1.0, 2
and 5 μM CsA. Control groups were treated with 2.5 μl dimethyl sulfoxide
(0.05%). Relative expression of CYP3A5 is presented (mean ± SD) following
qRT-PCR assessment of the cDNA synthesized from total RNA isolated
from these larvae. Statistical significance (P < 0.05) is indicated (*). CsA,
cyclosporine A; qRT-PCR, reverse transcription–quantitative polymerase
chain reaction.

(Hagen et al., 2002). CsA produces hypoxia-like conditions in the
liver (Zhong et al., 2001), which causes depletion of mitochondrial
energy (Garnier et al., 1996; Murray and Paller, 1986). The reason
CsA amplified ketamine toxicity in the zebrafish larvae could be
attributed to ketamine’s ability to reduce ATP production along
with CsA’s inhibition of cardiac high-energy phosphate and Krebs’
cycle metabolism with decreased glutamate/glutamine
concentrations and mitochondrial oxidative phosphorylation with
reduction in ATP (Christians et al., 2004). CsA showed a dosedependent inhibition of oxidative phosphorylation and ATP
production in rat kidney mitochondria (Nassberger, 1990) and
inhibited cellular respiration with stimulation of ATPase activity in
isolated mitochondria from mice (Giorgio et al., 2010). These
scenarios could explain the beneficial effects of ALCAR on
ketamine-treated as well as ketamine/CsA co-treated larvae, which
are further supported by our earlier finding that ALCAR’s protective
effects appear to be dependent on ATP synthase activity in
zebrafish (Guo et al., 2017).
Additional support on CsA’s amplification of ketamine
toxicity derives from our observation that increasing doses of
CsA (0.5–5.0 μM) proportionately inhibited overall development

J. Appl. Toxicol. 2017

Figure 6. Ketamine and CsA upregulate CYP3A65 mRNA expression in the
absence of ALCAR. (A) Zebrafish larvae at 72 hpf were exposed for 24 h with
2 mM ketamine alone or in the presence of 0.5, 1.0, 2 and 5 μM CsA. Control
groups were treated with 2.5 μl dimethyl sulfoxide (0.05%). Relative
expression of CYP3A5 is presented (mean ± SD) following qRT-PCR
assessment of the cDNA synthesized from total RNA isolated from these
larvae. Statistical significance (P < 0.05) is indicated (*). (B) ALCAR
normalizes CYP3A65 mRNA expression induced by ketamine and CsA.
Zebrafish larvae at 72 hpf were exposed for 24 h with 2 mM ketamine in
the presence or absence of CsA (5 μM) and ALCAR (1.0 mM). Control groups
were treated with 2.5 μl dimethyl sulfoxide (0.05%). Relative expression of
CYP3A5 is presented (mean ± SD) following qRT-PCR assessment of the
cDNA synthesized from total RNA isolated from these larvae. Statistical
significance (P < 0.05) is indicated (*). ALCAR, acetyl L-carnitine; CsA,
cyclosporine A; qRT-PCR, reverse transcription–quantitative polymerase
chain reaction.

as reflected by body length in ketamine co-treated larvae. We have
shown earlier that changes in body length serves as a reliable
endpoint of developmental toxicity in zebrafish (Lantz-McPeak
et al., 2015). CsA disrupted Notch signaling resulting in vascular
collapse in the zebrafish embryos when treatment started on
freshly laid eggs that are at one-cell or early cleavage stages
(Pandey et al., 2015). It is not possible to compare these results with
ours, as we exposed whole organisms (24 hpf ) to CsA. Our study
can therefore come close to recapitulating a holistic response to
the drugs instead of a cellular response and is consistent with
one other report that embryos treated with CsA (10 μg ml1) from
the one-cell stage (freshly laid egg) appeared morphologically wild
type at 72 hpf (Beis et al., 2005). However, when static exposure
started at 6 hpf, we noticed developmental arrest that completely
blocked hatching with severe pericardial edema at 78 hpf (72 h
exposure) in the larvae treated with ketamine/CsA or ketamine
alone, all of which died the same day a few hours apart, although
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the ones treated with only 10 μM CsA were alive. The difference in
the tolerance to the effects of ketamine and ketamine/CsA
treatment of the 24 hpf embryos compared to the 6 hpf gastrulae
indicates that a whole organism responds to drugs differently
(possibly more specifically) from the developing gastrulae (6 hpf )
that have not developed any organ rudiments but are an assembly
of cells belonging to the embryonic germ layers (Keller et al., 2008).
Therefore, to test for toxicity of drugs, we prefer using 24 hpf
zebrafish embryos instead of the one-cell stage fertilized eggs or
the 6 hpf gastrulae aiming to recapitulate the human response to
the drugs with more specificity.
For mechanistic studies with larvae exposed to drugs, we chose
a maximum CsA dose of 5 μM to avoid severe body deformity or
lethality. We also began treatment to the drugs when the larval
age was 72 hpf. The 24 h treatment of the 72 hpf larvae that have
a functional liver was intended not only to generate quantifiable
moderate toxic endpoints but also to explore whether there was
any alteration in the specific drug-metabolizing CYP enzyme.
Exposure of 72 hpf larvae to 10 μM CsA only has been shown to
cause significant behavioral defects but no morphological
anomalies (Clift et al., 2015). Consistent with this report, our current
study showed that 10 μM CsA-treated larvae developed like control
larvae. With 5 μM CsA, there were no morphological defects and
the treated larvae were similar to controls (data not shown).
However, with ketamine and CsA (0.5–5.0 μM) co-treatment, the
larvae developed pericardial edema that was not present in the
controls or in the ALCAR co-treated larvae suggesting that CsA
accentuated the toxicity triggered by ketamine.
We then explored potential changes in the expression of the
specific drug metabolizing CYP enzyme as xenobiotic drugs given
concomitantly might compete for the same CYP binding sites
resulting in inhibition of the metabolism of co-administered drugs

(Hollenberg, 2002). In humans, CP450 3A4 (CYP3A4) is the
predominant CYP isoform in the liver and small intestine (Paine
et al., 1997). In 2005, a full-length CYP3A cDNA from zebrafish
was cloned, which was named as CYP3A65 (Tseng et al., 2005) by
the Cytochrome P450 Nomenclature Committee. The expression
pattern and xenobiotic sensitivity of CYP3A65 in the zebrafish early
life stages are similar to mammalian CYP3A4 (Chng et al., 2012;
Tseng et al., 2005). Many xenobiotics, including rifampicin,
dexamethasone and phenobarbital induce CYP3A4 gene
expression in mammals (Pichard et al., 1990) and CYP3A65 in
zebrafish (Tseng et al., 2005). Our current study showed that
ketamine and CsA dose-dependently induced CYP3A65
expression. When combined, ketamine and various doses of CsA
induced significantly increased CYP3A65 expression in the larvae
compared to control. Ketamine co-treatment with 2 and 5 μM
CsA doses resulted in further increase in CYP3A65 expression
suggesting that the adverse effects caused by ketamine/CsA
co-treatment may not be the consequence of slower drug
metabolism in the larvae. This concept was further supported by
the observation that ALCAR inhibited the upregulation in CYP3A65
expression induced by either ketamine or ketamine/CsA and
normalized its expression to control levels. Together these results
suggested that toxicities caused by ketamine/CsA drug interaction
might not be due to slower drug metabolism as CYP3A65
expression was upregulated, although hepatic dysfunction due
to abnormally high CYP3A65 induction can potentially be a
concern. It is also important to consider the fact that ketamine is
metabolized enantio-selectively to norketamine (Schmitz et al.,
2010), which is pharmacologically active as an NMDA receptor
antagonist (Woolf and Adams, 1987) and is capable of inducing
toxicity (Lin et al., 2014). Therefore, enhanced metabolism of
ketamine may still be a factor in toxicities observed in the larvae

Figure 7. Schematic presentation of a potential mechanism of ALCAR’s protective effects against ketamine/CsA toxicity in zebrafish larvae. In the zebrafish
embryos, ketamine as an antagonist of NMDA receptors is known to suppress MAPK/ERK, which is normalized in the presence of ALCAR. Both ketamine and
2+
CsA as antagonists of Ca signaling could additively suppress MAPK/ERK activity. There is an inverse relationship between MAPK/ERK activity and CYP3A4
(zebrafish CYP3A65) expression. Potentially, ALCAR by normalizing ketamine-induced MAPK/ERK suppression results in the expression of CYP3A65 at the
control level, which could contribute to ALCAR’s beneficial effects on ketamine toxicity that is further exacerbated by CsA. ALCAR, acetyl L-carnitine; CsA,
cyclosporine A; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; NMDA, N-methyl-D-aspartate. [Colour figure can be
viewed at wileyonlinelibrary.com]
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treated with ketamine/CsA. Whether norketamine affects other
targets usually not affected by ketamine needs to be determined,
although, if true, can explain the more pronounced ketamine/CsA
toxicity compared to ketamine toxicity alone.
Our previous studies showed a potential mechanism for the
effects of ketamine and ALCAR on mitogen-activated protein
kinase (MAPK)/extracellular signal-regulated kinase (ERK) linked
to Ca2+ in zebrafish (Guo et al., 2017; Kanungo et al., 2012).
Furthermore, a link between reduction in MAPK/ERK activity and
ketamine-induced neurotoxicity in mice has also been reported
(Straiko et al., 2009). Chemical inhibition of MAPK/ERK signaling
increased CYP3A4 expression in human liver cells (Woolsey et al.,
2013). As ketamine inhibits MAPK/ERK signaling in the zebrafish
embryos, which is countered by ALCAR (Kanungo et al., 2012), it
is possible that ketamine-induced reduction in MAPK/ERK
signaling upregulated CYP3A65 expression (Fig. 7). CsA has been
shown to suppress MAPK/ERK activity in human K562 cells
(Sawafuji et al., 2003). Both ketamine and CsA as inhibitors of
Ca2+ signaling suppress MAPK/ERK activity in rat brains (Zhao
et al., 2008). We have previously reported that ketamine-induced
toxicity could involve reduced intracellular Ca2+ as ketamine
antagonizes the Ca2+-permeable NMDA receptors (Guo et al.,
2017; Kanungo et al., 2012). In this context, the effects of ketamine
and CsA together on the inhibition of Ca2+ signaling could
potentially be additive resulting in further suppression of
MAPK/ERK leading to the upregulation of CYP3A65 expression
(Fig. 7). A direct role of increased CYP3A65 expression in
ketamine/CsA drug interaction-induced toxicities in the zebrafish
larvae needs to be determined using various inhibitors of CYP3A65
to reverse the toxicity. Nonetheless, the current study provides for
the first time an insight into the mechanism of ketamine/CsA
combination toxicity in vivo by reversing it with ALCAR that could
help understand human conditions resulting from drug–drug
interaction.
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